A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy

Archives of Internal Medicine

Volumn 161, Issue 9, 2001, Pages 1161-1172

  Glazier, M G ^a   Bowman, M A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ESTRADIOL; ESTROGEN; IPRIFLAVONE; PHYTOESTROGEN;

BREAST CANCER; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIET SUPPLEMENTATION; ESTROGEN THERAPY; FEMALE; HORMONE INHIBITION; HUMAN; MENOPAUSAL SYNDROME; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW;

EID: 0034923423     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.9.1161     Document Type: Review

References (104)

1. Postmenopausal estrogen therapy and cardiovascular disease
2. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in post menopausal women on estrogen replacement therapy (ERT)
3. Hormone therapy to prevent disease and prolong life in postmenopausal women
4. Hormone replacement therapy
5. Estrogen replacement therapy and longitudinal decline in visual memory: A possible protective effect?
6. Effect of estrogen during menopause on risk and age at onset of Alzheimer's disease
7. Postmenopausal estrogen replacement and tooth retention
8. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women
9. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
10. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy
11. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
12. Use of hormone replacement therapy by postmenopausal women in the United States
13. Compliance with hormone replacement therapy
14. Can we improve compliance with long term HRT?
15. Trends in alternative medicine use in the United States, 1990-1997
16. Herbs as medicines
17. Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions
18. Alternative treatments for menopausal symptoms: Systematic review of scientific and lay literature
19. Vitamin E and climacteric syndrome
20. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing
21. Evening primrose oil and treatment of PMS
22. Does dong quai have estrogenic effects in postmenopausal women? a double-blind placebocontrolled trial
23. Mammalian lignan production from various foods
24. Phytoestrogens
25. Phytoestrogens: The biochemistry, physiology, and implications for human health of soy isoflavones
26. Naturally occurring estrogens in foods-a review
27. Biological effects of plant estrogens in pre menopausal women
28. Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women
29. Plasma concentrations of phyto-oestrogens in Japanese men
30. Estrogen and progestin bioactivity of foods, herbs and spices
31. Sex and long-term soy diets affect the metabolism and excretion of soy isoflavones in humans
32. Phytoestrogens: Epidemiology and a possible role in cancer protection
33. International comparison of mortality rates for cancer of the breast, ovary, prostate and colon, per capita fat consumption
34. Western diet and western diseases: Some hormonal and biochemical mechanisms and associations
35. Estrogen replacement therapy indications, contraindications and agent selection
36. Climacteric and menopause in seven southeast Asian countries
37. Multiethnic studies of diet, nutrition cancer in Hawaii
38. Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer
39. Biochemical targets of the isoflavone genistein in tumor cell lines
40. Soy intake and cancer risk: A review of the in vitro and in vivo data
41. Soy, its components, and cancer prevention: A review of the in vitro, animal and human data
42. Inhibition of tumor promoter induced hydrogen peroxide formation in vitro and in vivo by genestein
43. Use and specificity of genistein as inhibitor of protein-tyrosine kinases
44. Soy intake and risk of breast cancer in Asians and Asian Americans
45. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast
46. Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro
47. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo
48. Molecular effects of genistein on estrogen receptor mediated pathways
49. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein
50. Genistein induces maturation of cultured human breast cancer cells and prevents tumor growth in nude mice
51. Genistein studies in rats: Potential for breast cancer prevention and reproductive and developmental toxicity
52. The chemopreventive properties of soy isoflavonoids in animal models of breast cancer
53. Case-control study of phyto-oestrogens and breast cancer
54. Urinary excretion of isoflavonoids and the risk of breast cancer
55. Risk factors for breast cancer by age and menopausal status: A case-control study in Singapore
56. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiological evidence
57. Cardiovascular effects of soybean phytoestrogens
58. Decreased serum total cholesterol concentration is associated with high intake of soy products in Japanese men and women
59. Antioxidant activity of phytoestrogenic isoflavones
60. Soy protein and serum lipids
61. Biological effects of isoflavones in young women: Importance of the chemical composition of soyabean products
62. Thrombotic mechanisms in atherosclerosis: Potential impact of soy proteins
63. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women
64. In vitro bioassays of non-steroidal phytoestrogens
65. Inhibition of cholersterol absorbtion and synthesis in rats by sesamin
66. Soy and cholesterol reduction: Clinical experience
67. Overview of proposed mechanisms for the hypocholesterolemic effects of soy
68. Soy protein, isoflavones and cardiovascular disease risk
69. Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys
70. Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys
71. Soy protein versus soy phytoestrogens in the prevention of diet induced coronary artery atherosclerosis of male cynomolgus monkeys
72. Meta-analysis of the effects of soy protein intake on serum lipids
73. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women
74. Cholesterol-lowering effect of soy protein in normocholesterolemic and hypercholesterolemic men
75. Supplementation with isoflavonoid phytoestrogens does not alter serum lipid concentrations: A randomized controlled trial in humans
76. Western diet and Western diseases: Some hormonal and biochemical mechanisms and associations
77. Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques
78. 2-mediated human platelet responses
79. Ambiguities of aging: Japanese experience and perceptions of menopause
80. A randomized, double-blind, placebo-controlled, crossover study on the effect of oral estradiol on acute menopausal symptoms
81. The effect of dietary soy supplementation on hot flushes
82. Dietary flour supplementation decreases postmenopausal hot flushes: Effects of soy and wheat
83. Long-term estrogen replacement therapy prevents bone loss and fractures
84. Hip fractures in the elderly: A world-wide projection
85. Phytoestrogen excretion and rate of bone loss in postmenopausal women
86. Ipriflavone: Pharmacological properties and usefulness in postmenopausal osteoporosis
87. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis
88. Interactions between ipriflavone and the estrogen receptor
89. Lack of any estrogenic effect of ipriflavone in postmenopausal women
90. Inhibitory effect of ipriflavone on osteoclast-mediated bone resorption and new osteoclast formation in long-term cultures of mouse unfractionated bone cells
91. Inhibition of parathyroid hormone-stimulated resorption in cultured fetal rat long bones by the main metabolites of ipriflavone
92. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women
93. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years
94. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass
95. Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis
96. Effect of ipriflavone on bone mass in elderly osteoporotic women
97. An extract of soy flour influences serum cholesterol and thyroid hormones in rats and hamsters
98. Genistein augments cyclic adenosine 3′5′-monophosphate (cAMP) accumulation and insulin release in MIN6 cells
99. Detection of the effects of phytoestrogens on sheep and cattle
100. Potential adverse effects of phytoestrogens
101. Effects of soya consumption for one month on steroid hormones in premenopausal women: Implications for breast cancer risk reduction
102. Daidzein is a more bioavailable soymilk isoflavone than is genistein in adult women
103. Neonatal genistein chemoprevents mammary cancer
104. Bioavailability of soybean isoflavones depends upon gut microflora in women